0001724979 false 0001724979 2023-03-10 2023-03-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT 

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): March 10, 2023

 

 

 

Rain Oncology Inc. 

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   001-40356   82-1130967

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

8000 Jarvis Avenue, Suite 204 

Newark, CA 94560

(Address of Principal Executive Offices)

 

(510) 953-5559 

(Registrant’s telephone number, including area code)

 

N/A 

(Former Name or Former Address, if Changed Since Last Report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 210.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)		   Name of each exchange
on which registered
Common Stock, par value $0.001 per share   RAIN   The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

Rain Oncology Inc. (the “Company”) is aware of media reports indicating California’s banking regulator has taken possession of Silicon Valley Bank (“SVB”). The Company has no exposure to any liquidity concern at SVB.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: March 10, 2023 Rain Oncology Inc.
     
  By: /s/ Avanish Vellanki
    Avanish Vellanki
    Chairman and Chief Executive Officer

 

 

Grafico Azioni Rain Oncology (NASDAQ:RAIN)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Rain Oncology
Grafico Azioni Rain Oncology (NASDAQ:RAIN)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Rain Oncology